Table 3.

Histological characteristics of the study population

	IR (+) (n=210)		IR (-) (n=53)		Whole cohort (n=263)		p
	n	%	n	%	n	%
Length of specimen, mm	29 (7-65)		28 (17-49)		29 (7-65)		0.956
Number of portal tracts, median (IQR)	20 (6-41)		19 (11-20)		20 (6-41)		1.000
Grade of steatosis (S)
S1	33	15.7	20	37.7	53	20.2
S2	89	42.4	21	39.6	110	41.8	0.001
S3	88	41.9	12	22.6	1 00	38
Grade of activity (A)
A0	1	0.5	3	5.7	4	1.5
A1	15	7.1	12	22.6	27	10.3
A2	49	23.3	17	32.1	66	25.1	0.000
A3	74	35.2	16	30.2	90	34.2
A4	71	33.8	5	9.4	76	28.9
Stage of fibrosis (F)
F0	30	1 4.3	27	50.9	57	21.7
F1	74	35.2	17	32.1	91	34.6
F2	52	24.8	4	7.5	56	21.3	0.000
F3	42	20	5	9.4	47	17.9
F4	12	5.7	-	-	12	4.6
SAF algorithm classification
NAFL	20	9.5	15	28.3	35	13.3	0.000
NASH	1 90	90.5	38	71.7	228	86.7
Mild/Severe disease	16 (7.6)/194 (92.4)		14 (26.4)/39 (73.6)		30 (11.4)/233 (88.6)		0.000
Lobular inflammation
0	10	4.8	10	18.9	20	7.6
1	80	38.1	27	50.9	1 07	40.7	0.000
2	92	43.8	15	28.3	1 07	40.7
3	28	13.3	1	1.9	29	11
Ballooning
0	11	5.2	8	15.1	19	7.2
1	1 07	51	34	64.2	1 41	53.6	0.002
2	92	43.8	11	20.8	1 03	39.2
Portal inflammation
0	56	31.1	35	70	91	39.6
1	97	53.9	15	30	112	48.7	0.000
2	25	13.9	-	-	25	10.9
3	2	1.1	-	-	2	0.9
NAS score, median (IQR)	4	1-8	4	1-8	5	1-8	0.000
NASH CRN criteria
Non-NASH	7	3.3	8	15.1	15	5.7
Borderline NASH	55	26.2	23	43.4	78	29.7	0.000
Definite NASH	148	70.5	22	41.5	170	64.6
Significant fibrosis (≥F2)	106	50.5	9	17.0	115	43.7
Advanced fibrosis (≥F3)	54	25.7	5	9.4	59	22.4	0.011
Cirrhosis (F4)	12	5.7	-	-	12	4.6	0.075

CRN: Clinical research network; NAFL: Non-alcoholic fatty liver; NASH: Non-alcoholic steatohepatitis; SAF: Steatosis, activity and fibrosis; *: Sign indicates significant p-values as <0.05.